Biocon Closes $3bn Deal For Viatris Biosimilars

Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation

$3 billion icon blue
The deal value comprises $2bn cash upfront and a $1bn share issue • Source: Shutterstock

More from Deals

More from Business